Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Technology appraisal guidance
Reference number: TA137
Published: 27 February 2008

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders
17 January 2011
(57.5 Kb 16 sec)

Word Viewer may be required.

Word Viewer may be required.

This page was last updated: 17 January 2011